AstraZeneca

PM360 Magazine Announces Winners of 2021 Trailblazer Awards

Friday, September 24, 2021 - 1:00pm

NEW YORK, Sept. 24, 2021 /PRNewswire/ --PM360, a leading life sciences marketing industry trade publication, announced the winners of their 13th annual Trailblazer Awards during a virtual event on Thursday, September 23, 2021.

Key Points: 
  • NEW YORK, Sept. 24, 2021 /PRNewswire/ --PM360, a leading life sciences marketing industry trade publication, announced the winners of their 13th annual Trailblazer Awards during a virtual event on Thursday, September 23, 2021.
  • "This year's winners prove that even when circumstances are at their worst, our industry is capable of achieving extraordinary things.
  • Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry.
  • PM360 will publish profiles of this year's Trailblazer winners in its October issue and on its website.

Box to Host Virtual Investor Event at BoxWorks 2021

Thursday, September 23, 2021 - 9:05pm

Box (NYSE:BOX), the leading Content Cloud, today announced it will host a virtual investor event in conjunction with the companys user conference, BoxWorks 2021.

Key Points: 
  • Box (NYSE:BOX), the leading Content Cloud, today announced it will host a virtual investor event in conjunction with the companys user conference, BoxWorks 2021.
  • A live webcast of the event will be accessible from Boxs Investor Relations website at www.box.com/investors .
  • An archive of the webcast will also be available on Boxs Investor Relations website following the event.
  • During the course of this event, Box will make forward-looking statements regarding future events or the future financial performance of the company.

Dr. Mikael Dolsten Named to Agilent Board of Directors

Thursday, September 23, 2021 - 9:05pm

Dr. Dolsten brings 30 years of pharma experience to the Agilent board.

Key Points: 
  • Dr. Dolsten brings 30 years of pharma experience to the Agilent board.
  • Mikaels outstanding scientific, medical and research background makes him a valuable addition to the Agilent board, said Mike McMullen, Agilent president and CEO.
  • Were pleased to welcome Mikael to the Agilent board, said Koh Boon Hwee, chair of the Agilent board.
  • He is a member of the board of directors for Karyopharm Therapeutics, as well as the board at Vimian Group.

Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Thursday, September 23, 2021 - 9:10pm

HAMILTON, ONandBOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference onWednesday, September 29, 2021at2:40pm ET.

Key Points: 
  • HAMILTON, ONandBOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference onWednesday, September 29, 2021at2:40pm ET.
  • A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA (pembrolizumab) in patients with solid tumors expressing IGF-1R.

Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs

Thursday, September 23, 2021 - 2:30pm

Albeit rare, life-threatening side effects, such as abnormal blood clotting or myocarditis can be the result from either recombinant full-length or partial Spike proteinwhich are found in currently available vaccines.

Key Points: 
  • Albeit rare, life-threatening side effects, such as abnormal blood clotting or myocarditis can be the result from either recombinant full-length or partial Spike proteinwhich are found in currently available vaccines.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • Biovaxysbelieves that the haptenized spike protein has much diminished ability to bind to ACE2, which would result in much diminished vaccine toxicity.
  • "The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects."

Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs

Thursday, September 23, 2021 - 2:30pm

VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- USA News Group  -  Despite the approval for the Comirnaty vaccine from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) by the FDA back in August, vaccine hesitancy in the USA persists and is unlikely to disappear. Now with what PFE/BNTX are calling encouraging results for their Covid-19 vaccine trial on kids in hand, it's expected that parents are going to be even more hesitant to jab their own children. Reports of heart inflammation are adding fuel to the fire, spurning closer studies into myocarditis risk taking place inIsrael and the USA, and Canada particularly with mRNA vaccines such as those from Pfizer, BioNTech and Moderna, Inc. (NASDAQ:MRNA), while earlier this year multiple European countries suspended the use of AstraZeneca PLC (NASDAQ:AZN) over worries about blood clots. While these manufacturers are standing by their safety and efficacy, a new study on the hapten-modified spike protein used in the BVX-0320 SARS-CoV-2 vaccine from BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF) is giving hope to another method that could potentially mitigate some of these abnormal life-threatening side effects.

Key Points: 
  • Albeit rare, life-threatening side effects, such as abnormal blood clotting or myocarditis can be the result from either recombinant full-length or partial Spike proteinwhich are found in currently available vaccines.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • Biovaxysbelieves that the haptenized spike protein has much diminished ability to bind to ACE2, which would result in much diminished vaccine toxicity.
  • "The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects."

IDC MarketScape Positions Model N as a Leader in B2B Price Optimization and Management Applications

Thursday, September 23, 2021 - 2:00pm

Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced that it has been positioned as a Leader in the IDC MarketScape: Worldwide B2B Price Optimization and Management Applications 2021 Vendor Assessment.

Key Points: 
  • Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced that it has been positioned as a Leader in the IDC MarketScape: Worldwide B2B Price Optimization and Management Applications 2021 Vendor Assessment.
  • The IDC MarketScape evaluation criteria for the B2B Price Optimization and Management Applications includes architecture and platform strategy, customer delivery strategy, financial stability, functionality, solution portfolio growth, geographical expansion, future capabilities, and value.
  • For more information about the 2021 IDC MarketScape for B2B Price Optimization and Management Applications, please access this IDC MarketScape page .
  • Source: IDC MarketScape for B2B Price Optimization and Management Applications 2021 Vendor Assessment, doc #US46742021, September 2021.

RaySecur Raises $13M to Accelerate Market Adoption of Its Groundbreaking Mail and Package Threat Detection Platform Used by Four of the Largest US Companies

Thursday, September 23, 2021 - 2:00pm

Mail and package scanning, while vitally important to the security of governments, corporations, institutions, and individuals alike, remains a highly underserved and oft-overlooked sector.

Key Points: 
  • Mail and package scanning, while vitally important to the security of governments, corporations, institutions, and individuals alike, remains a highly underserved and oft-overlooked sector.
  • The Series A proceeds will also help RaySecur expand its mail screening-as-a-service solutions enabled by MailSecur including AI threat detection and EODSecurTM.
  • RaySecur is revolutionizing security imaging with the world's first DHS Safety Act-designated millimeter wave scanners and remote analysis and threat detection solutions.
  • RaySecur and MailSecur are trademarks of RaySecur, Inc. For more information on RaySecur and MailSecur, visit www.RaySecur.com .

BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA

Thursday, September 23, 2021 - 1:00pm

In addition, their proprietary exosome-based diagnostic that detects and quantifies markers of neuroinflammation and neurodegeneration facilitates patient selection and treatment monitoring.

Key Points: 
  • In addition, their proprietary exosome-based diagnostic that detects and quantifies markers of neuroinflammation and neurodegeneration facilitates patient selection and treatment monitoring.
  • BIORCHESTRA has been recently recognized for its achievements by Johnson & Johnson in their Innovation QuickFire Challenge in Neuroscience in June, 2021.
  • [i][ii]
    Reflecting the success of its research and development programs and anticipating its international expansion and entry into clinical development, the BIORCHESTRA has appointed Dr. Louis St.L.
  • O'Dea (MB, BCh, BAO, FRCP has worked as CMO in global pharmaceutical companies such as Serono, Moderna, Akcea (Ionis), Radius and Oxford Immunotec for 28 years.

VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform

Thursday, September 23, 2021 - 7:00am

LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products.

Key Points: 
  • LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products.
  • The strategic, long-term research collaboration with AstraZeneca aims to optimise and validate VaxEquity's saRNA platform and apply it to advance novel therapeutic programmes.
  • AstraZeneca will support VaxEquity with research and development funding and has the option to collaborate with VaxEquity on up to 26 drug targets.
  • Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said "This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox.